Letrozole 2.5 mg/tab – US Stock
$21.55
Letrozole 2.5 mg/tab is an oral tablet formulation containing letrozole, a non-steroidal aromatase inhibitor. Each tablet contains 2.5 mg of active ingredient, with 30 tablets per pack and a stated active half-life of approximately 2–3 days. Manufactured by Hilma Biocare and listed as US Stock.
Letrozole 2.5 mg/tab – US Stock
Letrozole 2.5 mg/tab from Hilma Biocare is an oral tablet formulation containing letrozole, a non-steroidal aromatase inhibitor. Each tablet contains 2.5 mg of active ingredient, and the product is supplied in a 30-tablet pack.
Product Overview
Letrozole is a non-steroidal aromatase inhibitor that acts on the aromatase pathway involved in estrogen production. The supplied product description identifies letrozole as a compound originally developed for medical use in the management of certain hormone-sensitive breast cancers.
The product specifications state an active half-life of approximately 2–3 days. Letrozole is supplied as an oral tablet and is specified as having no water retention or aromatization.
Active Ingredient
The active ingredient is Letrozole, a non-steroidal aromatase inhibitor.
Dosage Form and Strength
Letrozole is supplied as an oral tablet containing 2.5 mg of active ingredient per tablet.
Product Characteristics
According to the supplied specifications, Letrozole has the following characteristics:
- Non-steroidal aromatase inhibitor
- Oral tablet formulation
- 2.5 mg letrozole per tablet
- Approximately 2–3-day active half-life
- 30 tablets per pack
- No water retention listed
- No aromatization listed
Product Specifications
| Specification | Details |
|---|---|
| Brand | Hilma Biocare |
| Active Ingredient | Letrozole |
| Group | Aromatase inhibitor |
| Form | Oral tablet |
| Strength | 2.5 mg per tablet |
| Active Half-Life | Approximately 2–3 days |
| Pack Size | 30 tablets |
| Water Retention | No, according to supplied specifications |
| Aromatization | No, according to supplied specifications |
| Stock | US Stock |
Product Characteristics
Letrozole works by inhibiting aromatase, the enzyme responsible for converting certain androgens into estrogens. As an aromatase inhibitor, its primary pharmacological characteristic is its effect on estrogen synthesis.
The supplied source material discusses letrozole in relation to estrogen management and bodybuilding applications. These descriptions are presented for product context only and should not be interpreted as recommendations for anabolic-steroid use, post-cycle therapy, or self-treatment.
Reported Side Effects
The supplied product information identifies the following possible adverse effects:
- Skin rash
- Nausea
- Abdominal pain
- Fatigue
- Dizziness
- Headache
- Increased low-density lipoprotein (LDL) cholesterol
- Elevated liver enzymes
Because letrozole can substantially alter estrogen levels, individual risks and suitability may vary. Appropriate medical evaluation and professional monitoring should be considered.
Important Information
Letrozole is a pharmacologically active aromatase inhibitor. The information on this page is provided for product identification and factual specification purposes only and does not constitute personalized medical advice.
No dosing recommendations, treatment protocols, steroid-cycle instructions, post-cycle therapy protocols, or stacking regimens are provided. The supplied source discusses combining letrozole with other compounds; these combinations are not presented here as recommendations.
About Hilma Biocare USA
Letrozole 2.5 mg/tab is part of the Hilma Biocare product range. Each tablet contains 2.5 mg of letrozole, and the product is supplied in a 30-tablet pack with a stated active half-life of approximately 2–3 days, listed as US Stock.
Reviews
There are no reviews yet.